EP2408796 - Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III [Right-click to bookmark this link] | |||
Former [2012/04] | TARGETING APOLIPOPROTEIN B FOR THE REDUCTION OF APOLIPOPROTEIN C-III | ||
[2018/47] | Status | No opposition filed within time limit Status updated on 26.02.2021 Database last updated on 02.09.2024 | |
Former | The patent has been granted Status updated on 20.03.2020 | ||
Former | Grant of patent is intended Status updated on 24.10.2019 | ||
Former | Examination is in progress Status updated on 09.08.2019 | ||
Former | Grant of patent is intended Status updated on 17.12.2018 | Most recent event Tooltip | 14.06.2024 | Lapse of the patent in a contracting state New state(s): TR | published on 17.07.2024 [2024/29] | Applicant(s) | For all designated states Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US | For all designated states President and Fellows of Harvard College Holyoke Center, 727 1350 Massachusetts Ave. Cambridge, MA 02138 / US | [2019/02] |
Former [2016/07] | For all designated states Ionis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US | ||
For all designated states The President and Fellows of Harvard College Holyoke Center, Suite 727 1350 Massachusetts Avenue Cambridge, MA 02138 / US | |||
Former [2012/04] | For all designated states Isis Pharmaceuticals, Inc. 2855 Gazelle Court Carlsbad, CA 92010 / US | ||
For all designated states The President and Fellows of Harvard College Holyoke Center, Suite 727 1350 Massachusetts Avenue Cambridge, MA 02138 / US | Inventor(s) | 01 /
SACKS, Frank, M. 129 Leonard Street Belmont MA 02478 / US | 02 /
TRIBBLE, Diane 5154 Whitman Way 313 Carlsbad CA 92008 / US | [2012/04] | Representative(s) | Chapman, Desmond Mark, et al Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2020/17] |
Former [2012/04] | Chapman, Desmond Mark, et al Carpmaels & Ransford One Southampton Row London WC1B 5HA / GB | Application number, filing date | 10754009.8 | 16.03.2010 | [2020/17] | WO2010US27541 | Priority number, date | US20090160671P | 16.03.2009 Original published format: US 160671 P | [2012/04] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2010107838 | Date: | 23.09.2010 | Language: | EN | [2010/38] | Type: | A1 Application with search report | No.: | EP2408796 | Date: | 25.01.2012 | Language: | EN | The application published by WIPO in one of the EPO official languages on 23.09.2010 takes the place of the publication of the European patent application. | [2012/04] | Type: | B1 Patent specification | No.: | EP2408796 | Date: | 22.04.2020 | Language: | EN | [2020/17] | Search report(s) | International search report - published on: | US | 23.09.2010 | (Supplementary) European search report - dispatched on: | EP | 19.12.2012 | Classification | IPC: | A61K31/7088, A61P9/00, A61P3/08, A61P3/06 | [2018/46] | CPC: |
A61K31/7088 (EP,US);
A61P3/06 (EP);
A61P3/08 (EP);
A61P3/10 (EP);
A61P9/00 (EP)
|
Former IPC [2013/03] | C07H21/04, A61K31/7088, A61P9/00 | ||
Former IPC [2012/04] | C07H21/04, A61K31/7088 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR [2012/04] | Extension states | AL | Not yet paid | BA | Not yet paid | ME | Not yet paid | RS | Not yet paid | Title | German: | Targeting Apolipoprotein B für die Reduktion von Apolipoprotein C-III | [2018/46] | English: | Targeting Apolipoprotein B for the reduction of Apolipoprotein C-III | [2018/47] | French: | Ciblage de l'Apolipoprotéine B pour la réduction de l'apolipoprotéine C-III | [2018/47] |
Former [2012/04] | APOLIPOPROTEIN-B-TARGETIN ZUR REDUKTION VON APOLIPOPROTEIN C-III | ||
Former [2012/04] | TARGETING APOLIPOPROTEIN B FOR THE REDUCTION OF APOLIPOPROTEIN C-III | ||
Former [2012/04] | CIBLAGE DE L'APOLIPOPROTÉINE B POUR LA RÉDUCTION DE L'APOLIPOPROTÉINE C-III | Entry into regional phase | 10.10.2011 | National basic fee paid | 10.10.2011 | Search fee paid | 10.10.2011 | Designation fee(s) paid | 10.10.2011 | Examination fee paid | Examination procedure | 10.10.2011 | Examination requested [2012/04] | 17.07.2013 | Amendment by applicant (claims and/or description) | 31.07.2014 | Despatch of a communication from the examining division (Time limit: M06) | 21.05.2015 | Reply to a communication from the examining division | 10.10.2018 | Cancellation of oral proceeding that was planned for 18.10.2018 | 18.10.2018 | Date of oral proceedings (cancelled) | 18.12.2018 | Communication of intention to grant the patent | 03.06.2019 | Despatch of communication that the application is deemed to be withdrawn, reason: fee for grant / fee for printing not paid in time | 07.08.2019 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 25.10.2019 | Communication of intention to grant the patent | 25.02.2020 | Fee for grant paid | 25.02.2020 | Fee for publishing/printing paid | 25.02.2020 | Receipt of the translation of the claim(s) | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 31.07.2014 | Opposition(s) | 25.01.2021 | No opposition filed within time limit [2021/13] | Request for further processing for: | The application is deemed to be withdrawn due to failure to fulfill actions required for granting the patent | 07.08.2019 | Request for further processing filed | 07.08.2019 | Full payment received (date of receipt of payment) Request granted | 19.08.2019 | Decision despatched | The application is deemed to be withdrawn due to failure to reply to the examination report | 21.05.2015 | Request for further processing filed | 21.05.2015 | Full payment received (date of receipt of payment) Request granted | 08.06.2015 | Decision despatched | Fees paid | Renewal fee | 07.03.2012 | Renewal fee patent year 03 | 30.01.2013 | Renewal fee patent year 04 | 30.01.2014 | Renewal fee patent year 05 | 06.03.2015 | Renewal fee patent year 06 | 10.03.2016 | Renewal fee patent year 07 | 10.03.2017 | Renewal fee patent year 08 | 13.03.2018 | Renewal fee patent year 09 | 13.03.2019 | Renewal fee patent year 10 | 12.03.2020 | Renewal fee patent year 11 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 16.03.2010 | AT | 22.04.2020 | CY | 22.04.2020 | CZ | 22.04.2020 | DK | 22.04.2020 | EE | 22.04.2020 | ES | 22.04.2020 | FI | 22.04.2020 | HR | 22.04.2020 | IT | 22.04.2020 | LT | 22.04.2020 | LV | 22.04.2020 | MC | 22.04.2020 | MK | 22.04.2020 | NL | 22.04.2020 | PL | 22.04.2020 | RO | 22.04.2020 | SE | 22.04.2020 | SI | 22.04.2020 | SK | 22.04.2020 | SM | 22.04.2020 | TR | 22.04.2020 | BG | 22.07.2020 | NO | 22.07.2020 | GR | 23.07.2020 | IS | 22.08.2020 | PT | 24.08.2020 | [2024/29] |
Former [2024/22] | HU | 16.03.2010 | |
AT | 22.04.2020 | ||
CY | 22.04.2020 | ||
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
MC | 22.04.2020 | ||
MK | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SI | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2023/27] | HU | 16.03.2010 | |
AT | 22.04.2020 | ||
CY | 22.04.2020 | ||
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
MC | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SI | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2023/24] | AT | 22.04.2020 | |
CY | 22.04.2020 | ||
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
MC | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SI | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/45] | AT | 22.04.2020 | |
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
MC | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SI | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/24] | AT | 22.04.2020 | |
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SI | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/10] | AT | 22.04.2020 | |
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
PL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SK | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/09] | AT | 22.04.2020 | |
CZ | 22.04.2020 | ||
DK | 22.04.2020 | ||
EE | 22.04.2020 | ||
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
IT | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/08] | DK | 22.04.2020 | |
ES | 22.04.2020 | ||
FI | 22.04.2020 | ||
HR | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
RO | 22.04.2020 | ||
SE | 22.04.2020 | ||
SM | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2021/01] | FI | 22.04.2020 | |
HR | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
SE | 22.04.2020 | ||
BG | 22.07.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2020/50] | FI | 22.04.2020 | |
HR | 22.04.2020 | ||
LT | 22.04.2020 | ||
LV | 22.04.2020 | ||
NL | 22.04.2020 | ||
SE | 22.04.2020 | ||
NO | 22.07.2020 | ||
GR | 23.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2020/48] | FI | 22.04.2020 | |
LT | 22.04.2020 | ||
NL | 22.04.2020 | ||
SE | 22.04.2020 | ||
NO | 22.07.2020 | ||
IS | 22.08.2020 | ||
PT | 24.08.2020 | ||
Former [2020/47] | LT | 22.04.2020 | |
NO | 22.07.2020 | ||
IS | 22.08.2020 | ||
Former [2020/46] | IS | 22.08.2020 | Documents cited: | Search | [XI]US2006035858 (GEARY RICHARD S [US], et al) [X] 1-11 * claims 1-35 * * page 14, paragraph 270 * [I] 12-15; | [I] - CHAN DICK C ET AL, "Apolipoprotein B-100 kinetics in visceral obesity: Associations with plasma apolipoprotein C-III concentration", METABOLISM, CLINICAL AND EXPERIMENTAL, W.B. SAUNDERS CO., PHILADELPHIA, PA, US, (20020801), vol. 51, no. 8, doi:10.1053/META.2002.33339, ISSN 0026-0495, pages 1041 - 1046, XP002508090 [I] 12-15 * page 1054, paragraph 4 * DOI: http://dx.doi.org/10.1053/meta.2002.33339 | [I] - MERKI E (MERKI ESTHER)1 ET AL, "A second generation antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on apolipoprotein B-100 particles in lipoprotein(a)-transgenic mice", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, ELSEVIER, NEW YORK, NY, US, (20080311), vol. 51, no. 10, Suppl.1, ISSN 0735-1097, page A294, XP009165215 [I] 12-15 * the whole document * | [I] - anonymous, "ISIS-301012", (2007), PROUS, URL: http://integrity.thomson-pharma.com/integrity/xmlxsl/pk_ref_list.xml_show_ficha_ref?p_ref_id=1132978, (20121129), XP002688241 [I] 12-15 * the whole document * | International search | [Y]US2006035858 (GEARY RICHARD S [US], et al); | [Y]US2008146788 (BHAT BALKRISHEN [US], et al); | [Y] - CHAN ET AL., APOLIPOPROTEIN B-100 KINETICS IN VISCERAL OBESITY: ASSOCIATIONS WITH PLASMA APOLIPOPROTEIN C-III CONCENTRATION METABOLISM, (200208), vol. 51, no. 8, pages 1041 - 1046, XP002508090 DOI: http://dx.doi.org/10.1053/meta.2002.33339 | by applicant | WO9914226 | WO03004602 | WO2004044181 | US2005130923 | US2006035858 | WO2007134181 | WO2008101157 | - KNOPP, New Engl. J. Medicine,, (19990000), vol. 341, pages 498 - 511 | - DAVIS; HUI, Arterioscler. Thromb. Vase. Biol., (20010000), vol. 21, pages 887 - 898 | - BONOW, Circulation, (20020000), vol. 106, pages 3140 - 3141 | - DAVIDSON; SHELNESS, Annu. Rev. Nutr., (20000000), vol. 20, pages 169 - 193 | - CAMPOS et al., "Distinct patterns of lipoproteins with apoB defined by presence of apoE or apoC-III in hypercholesterolemia and hypertriglyceridemia", J. Lipid Res., (20010000), vol. 42, pages 1239 - 1249 | - Arch. Int. Med., (19880000), vol. 148, pages 36 - 39 | - LEE et al., Arteriosclerosis, Thrombosis, and Vascular Biology, (20030000), vol. 23, pages 853 - 858 | - YAMAMOTO et al., Diabetes, (20030000), vol. 52, pages 1155 - 1162 | - PITTNER et al., Int. J. Obes. Relat. Metab. Disord., (20040000), vol. 28, pages 963 - 71 | - HEYMSFIELD S B, Archives of Internal Medicine, (20000000), vol. 160, pages 1321 - 1326 | - "GenBank", Database accession no. NM 000384.1 | - "GenBank", Database accession no. NM_000384.1 | - "GenBank", Database accession no. NM -000384.2 | - "GenBank", Database accession no. M19734.1 | - "GenBank", Database accession no. Ml 8471.1 | - "GenBank", Database accession no. Ml 7779.1 | - "GenBank", Database accession no. X04714.1 | - "GenBank", Database accession no. M14162.1 | - "GenBank", Database accession no. NT 022227.9 | - "GenBank", Database accession no. AI249040.1 | - WOOLF et al., Proc. Natl. Acad. Sci. USA, (19920000), vol. 89, pages 7305 - 7309 | - GAUTSCHI et al., J. Natl. Cancer Inst., (20010300), vol. 93, pages 463 - 471 | - MAHER; DOLNICK, Nuc. Acid. Res., (19880000), vol. 16, pages 3341 - 3358 | - Sanghvi, Y.S., Crooke, S.T. and Lebleu, B.,, Antisense Research and Applications, CRC Press, (19930000), pages 276 - 278 | - ALTSCHUL et al., J. Mol. Biol., (19900000), vol. 215, page 403 410 | - ZHANG; MADDEN, Genome Res., (19970000), vol. 7, page 649 656 | - SMITH; WATERMAN, Adv. Appl. Math., (19810000), vol. 2, page 482 489 | - JONES, L.J. et al., Analytical Biochemistry, (19980000), vol. 265, pages 368 - 374 | - "GenBank", Database accession no. M 14162.1 | - CAMPOS et al., "Distinct patterns of lipoproteins with ApoB defined by presence of ApoE or ApoC-III in hypercholesterolemia and hypertriglyceridemia", J. Lipid Res., (20010000), vol. 42, pages 1239 - 1249 | - KHOO et al., "Effects of estrogenic oral contraceptives on the lipoprotein B particle system defined by apolipoproteins E and C-III content", J. Lipid Res., (19990000), vol. 40, pages 202 - 212, XP008130379 | - "The isolation and quantitative analysis of serum lipoproteins", LINDGREN, F. T.; L. C. JENSEN; F. T. HATCH., Blood Lipids and Lipoproteins: Quantitation, Composition, and Metabolism, John Wiley-Interscience, (19720000), pages 181 - 274 | - "GenBank", Database accession no. L04150.1 | US20030712795 | US20040553722 | US20050123656 | US20050573537 | US20050200710 |